Skip to main content

Research Repository

Advanced Search

Dr NABIL FADAI's Outputs (3)

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial (2021)
Journal Article
Ramakrishnan, S., Nicolau, D. V., Langford, B., Mahdi, M., Jeffers, H., Mwasuku, C., Krassowska, K., Fox, R., Binnian, I., Glover, V., Bright, S., Butler, C., Cane, J. L., Halner, A., Matthews, P. C., Donnelly, L. E., Simpson, J. L., Baker, J. R., Fadai, N. T., Peterson, S., …Bafadhel, M. (2021). Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respiratory Medicine, 9(7), 763-772. https://doi.org/10.1016/s2213-2600%2821%2900160-0

Background: Multiple early reports of patients admitted to hospital with COVID-19 showed that patients with chronic respiratory disease were significantly under-represented in these cohorts. We hypothesised that the widespread use of inhaled glucocor... Read More about Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.

Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19 (2021)
Journal Article
Fadai, N. T., Sachak-Patwa, R., Byrne, H. M., Maini, P. K., Bafadhel, M., & Nicolau, D. V. (2021). Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. Journal of the Royal Society, Interface, 18(175), Article 20200950. https://doi.org/10.1098/rsif.2020.0950

While the pathological mechanisms in COVID-19 illness are still poorly understood, it is increasingly clear that high levels of pro-inflammatory mediators play a major role in clinical deterioration in patients with severe disease. Current evidence p... Read More about Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19.